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In its brief lifetime as a known peptide, soma-
tostatin has provided a truly remarkable story filled 
with surprising developments from unexpected quar-
ters. The foundation was set in 1969, when Krulich 
and McCann 1 reported that fractions of a crude hy-
pothalamic extract inhibited the secretion of growth 
hormone. In 1973, Guillemin's laboratory reported 
the sequence and synthesis of a fourteen amino acid 
peptide with the same inhibitory effect.2·3 It occurs in 
both a cyclic and linear form, each displaying equal 
biological activity. Somatostatin was assigned as its 
name, but it is also commonly referred to as growth 
hormone release inhibitory factor (G H RI F) or soma-
totropin-release inhibiting factor (SRIF). 
Characterization of somatostatin's biological ac-
tivity proceeded rapidly once the synthetic peptide 
became available. It proved to be a potent inhibitor 
of thyroid stimulating hormone (TSH). 4 No effect 
was found upon prolactin or adrenocorticotropic 
hormone (ACTH) secretion except in the patholog-
ical situations of acromegaly5 and Nelson's syn-
drome,6 where inhibition has been described. The 
secretion of follicle-stimulating hormone (FSH) and 
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luteinizing hormone (LH) is not inhibited by soma-
tostatin.7 There was great surprise when investigators 
in Seattle, working with baboons, found that soma-
tostatin inhibited the secretion of two pancreatic hor-
mones, insulin and glucagon, 8 and, as studies ex-
panded to other organs, the inhibition of gastrin, 9 
secret in , 10 gastric acid and pepsin secretion, 9 and se-
cretin-stimulated exocrine pancreatic secretion 10 were 
described. Very little is known about the molecular 
mechanisms of somatostatin effects, but clues are 
being provided by the findings that inhibition of in-
sulin secretion can be partially reversed by high cal-
cium concentration 11 and by alpha adrenergic block-
ade with phentolamine.12 Furthermore, somatostatin 
appears to interfere with calcium uptake by islets 13 
and may inhibit tissue cyclic adenosine mono-
phosphate (AMP) accumulation. 14 Both events are 
thought to be important in the secretory process. 
Diabetes researchers became interested when it 
was shown that somatostatin infusions caused a fall 
of blood glucose in both normal subjects and diabet-
ics .15 In addition, somatostatin markedly slowed the 
development of ketoacidosis in insulin-deprived juve-
nile-type diabetics, 16 even though it did little to re-
verse established ketoacidosis. 17 Until then there was 
no convincing evidence that glucagon was anything 
5 
6 
more than a vestigial hormone, only continual de-
bates about the theoretical relative contributions of 
insulin and glucagon to metabolic processes. 
The widespread effects of insulin upon hepatic 
and peripheral tissues are well known, but glucagon's 
effects appear to be more limited. Although pharma-
cological amounts of glucagon can influence many 
organs, physiological concentrations act primarily on 
the liver, and probably have minor lipolytic effects on 
adipose tissue. Hepatic glycogenolysis and gluco-
neogenesis can both be stimulated by glucagon, thus 
leading to enhanced hepatic glucose output. It is also 
now clear that glucagon has a direct stimulatory ef-
fect upon hepatic ketogenesis.18 The issue, however, is 
whether these effects are trivial and easily nullified by 
small amounts of insulin or whether they are phys-
iologically important. Somatostatin has become a 
useful pharmacological tool to help answer these 
questions, because in addition to being able to block 
insulin and glucagon secretion, it has no known di-
rect effect upon hepatic glucose output or peripheral 
glucose utilization. Several laboratories have now 
shown that the fall of blood glucose during a soma-
tostatin infusion is secondary to a reduction of he-
patic glucose output. The interpretation has therefore 
been made that inhibition of glucagon in these short-
term experiments was more important than the inhi-
bition of insulin. A similar fall in glucose was found 
in a diabetic with hypophysectomy, indicating that 
growth hormone inhibition did not have much in-
fluence.15 
These unexpected findings made it difficult to 
understand why patients with pancreatectomies were 
hyperglycemic. According to the results of the soma-
tostatin experiments, the removal of both insulin and 
glucagon surgically should have led to hypoglycemia. 
One finding used to reconcile this puzzle was that 
insulin-deprived pancreatectomized dogs have abun-
dant amounts of extra-pancreatic glucagon which is 
known to be primarily of gastric origin. 19 Humans, 
however, appear to have very little gastric glucagon.20 
The best explanation for the paradox appears to be 
that glucagon's effects are only transient; thus, a 
glucagon infusion leads to an increase of hepatic 
glucose output which lasts for about an hour.21 Sim-
ilarly, if glucagon is "removed" with somatostatin, 
there is a transient reduction in hepatic glucose out-
put.22 Therefore, during chronic somatostatin in-
fusions, a fall of blood glucose is seen before hy-
perglycemia, which appears as insulin deficiency 
dominates.22 These experiments and others have led 
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some to say that glucagon's influence on blood glu-
cose homeostasis is minor and that the hyperglycemia 
of diabetes is almost entirely secondary to insulin 
deficiency. The acceptance of a dominant role for 
insulin seems inescapable, but glucagon may still 
have important effects. Daily physiological events 
bear little relation to infusions of glucagon or soma-
tostatin; glucagon concentrations do not remain con-
stant during the day but fluctuate considerably, par-
ticularly with meals. Thus, if each one of these 
fluctuations led to a transient effect on blood glucose 
lasting for even 45 mintues, it is clear that glucagon 's 
overall influence throughout the day could be sub-
stantial. Furthermore, there is abundant evidence 
that glucagon secretion is increased in diabetes.23 To 
answer some of these critical questions, workers have 
given glucagon infusions and injections, trying to stay 
within the concentrations thought to be phys-
iologicaJ.2•- 25 There is agreement that glucagon has 
hyperglycemic effects when unopposed by insulin but 
disagreement that it causes deterioration of control 
during insulin therapy in diabetics. In addition, there . 
is growing acceptance that endogenous insulin secre-
tion in normal subjects can effectively counter the 
effects of artificially-raised plasma glucagon concen-
trations. Therefore, despite large amounts of recent 
work, there remains much disagreement about gluca-
gon's importance in diabetes. 
This rather elaborate background is necessary to 
understand somatostatin's possible usefulness as a 
therapeutic agent. Its ability to lower blood glucose is 
presumed to be mediated primarily via glucagon inhi-
bition. Therefore the question of glucagon's contri-
bution to the hyperglycemia of diabetes is of utmost 
importance. During debates about somatostatin's po-
tential in diabetes a commonly raised question is, 
"Why worry about somatostatin? Why not give more 
insulin?" Somatostatin 's advocates argue that follow-
ing each meal there is a glucagon rise which drives 
blood glucose to unacceptable postprandial peaks 
even in so-called well-controlled diabetics. Aborting 
these glucagon rises with somatostatin would there-
fore minimize glucose excursions in a way unachiev-
able with conventional insulin therapy. New data 
adding more confusion to these concepts is the find-
ing that somatostatin can impair carbohydrate ab-
sorption by the gastrointestinal tract and may lower 
postprandial glucose by a mechanism independent of 
glucagon.27 
As indicated above, much of the controversy 
about somatostatin centers on its possible effects 
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upon glucose control irt di abetes. Even though data 
showing a connection between blood glucose and 
complications is not conclusive, there is enough cir-
cumstantial evidence to warrant the pursuit of op-
timal control. Another factor linked to complications 
is growth hormone. Even though large, well-con-
trolled studies are still not available, the weight of 
evidence suggests that pituitary ablation has a benefi-
cial effect upon diabetic retinopathy. Possibly impor-
tant as well is the observation that plasma growth 
hormone levels are increased in diabetics , when con-
trol is poor28 or during exercise. 29·30 Somatostatin 
therefore may possibly benefit diabetics through two 
mechanisms-control of blood glucose and suppres-
sion of growth hormone secretion. 
Obviously much more work is needed before 
somatostatin's ultimate value as a therapeutic tool 
can be assessed and there are many hurdles which 
need to be overcome. Long-acting preparations must 
be developed , as injections before each meal are ob-
viously impractical. A protamine-zinc somatostatin 
preparation has been found to increase the duration 
of action in rats31 but has been unsuccessful in pri-
mates. There were early fears that inhibitory effects 
upon platelet function would lead to serious bleeding 
problems, but recent thorough studies have dispelled 
some of these anxieties. 32 Even though chronic sup-
pression of growth hormone might help some diabet-
ics, growth retardation in children would not be ac-
ceptable. Furthermore, it is possible that 
somatostatin's effecis on the gastrointestinal tract 
will produce discomfort and maldigestion leading to 
nutritional deficiency. Efforts are underway to de-
velop somatostatin analogues which will selectively 
suppress glucagon secretion and, although selectivity 
has not yet been accomplished, a D-tryptophan8-
somatostatin analogue has been synthesized which is 
eight times more potent than somatostatin in inhib-
iting growth hormone, insulin, and glucagon secre-
tion.33 In addition to its potential usefulness in diabe-
tes, somatostatin may be of some benefit in the 
treatment of acromegaly,5 peptic ulcer disease, and 
metastatic insulinomas and glucogonomas. 
Another area of research has focused upon the 
localization of somatostatin. lmmunohistochemical 
techniques, in particular immunofluorescence, have 
been very useful for accurate localization, and radio-
immunoassay has permitted quantitation of soma-
tostatin immunoreactivity. The major obstacle in the 
development of radioimmunoassays was the problem 
of labeling somatostatin. Labeling with 1251 of the 
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tyrosine of the synthetic analogue 1-tyrosinated soma-
tostatin provided the breakthrough and several very 
specific, highly sensitive assay systems have become 
available through the research of Arimura et al34 and 
by Y.C. Patel, MD and S. Reichlin, MD (unpub-
lished data , 1975). 
These techniques led to an unexpected and im-
portant discovery in late 1974 when Dubois in 
France, using immunofluorescence, found soma-
tostatin immunoreactivity in discrete cells of the islets 
of Langerhans in several species. 35 This finding was 
rapidly confirmed in isolated islets with a specific 
radioimmunoassay. 36 Somatostatin was also found 
scattered throughout the gastrointestinal tract with 
unusually large amounts in the gastric antrum, 37 and 
in addition was found in numerous extrahypotha-
lamic areas of the central nervous system, 36·38 with 
especially large concentrations in the septum and pre-
optic area, the thalamus, and the cortex. The highest 
concentration of somatostatin in the hypothalamus 
has been localized to the median eminence and the 
arcuate nucleus. 38 Definitive proof that extra-
hypothalamic material with somatostatin immuno-
reactivity is identical to hypothalamic somatostatin 
awaits amino acid sequence determination . The ma-
terial does appear to have biological activity, how-
ever, as extracts of frog pancreas with a high content 
of somatostatin immunoreactivity have been found 
to inhibit growth hormone secretion. 39 
I mmunofluorescent techniques were also used to 
show that the cells containing somatostatin immuno-
reactivity in islets and gut were of the D-type. 40 D 
cells comprise about 5% to 10% of the mammalian 
islet cell population and tend to occur in close prox-
imity to glucagon-containing A cells. In the mouse 
and rat, for instance, A and D cells form a rim of 
tissue around a central core of B cells.41 In the horse, 
however, there is a central mass of A and D cells with 
peripheral cells being B cells, and in man A and D 
cells occur together next to capillary walls. The phys-
iological importance of this distribution is as yet un-
known, but it seems likely that there is some unique 
interaction between A and D cells. 
An exception to the above pattern is found in 
birds which have a population of islets, called light 
islets, with D cells and B cells, but almost no A cells.42 
There are also, however, dark islets containing both 
A and D cells and few B cells . Birds are also unique 
because their pancreases contain high concentrations 
of glucagon and somatostatin compared to mam-
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mals,43·44 but the significance of this can only be spec-
ulated upon. 
It was assumed by many that normal islet D cells 
contained gastrin, largely because the cells of gastrin-
containing tumors of the Zollinger-Ellison syndrome 
have D-cell-like morphology. Some workers have 
found gastrin immunoreactivity in islet tissue, 45 but a 
recent thorough study has been unable to confirm 
this .46 Thus, the origin of the gastrin-containing cells 
of the Zollinger-Ellison syndrome remains undiscov-
ered. 
There has been discussion about whether soma-
tostatin in extrahypothalamic cells is synthesized in 
situ or taken up following secretion by the hypothala-
mus. The latter possibility seemed less likely because 
of somatostatin's instability in blood and the finding 
that the concentration of somatostatin in islets is 
comparable to that found in the hypothalamus. Re-
cent studies in the angler fish indicate that somatosta-
tin is synthesized in islets. The angler fish is unique as 
it has enormous (100 to 200 mg) islets which can 
easily be dissected free and contain no pancreatic 
exocrine tissue. lmmunohistochemical studies have 
shown that approximately 30% of the cells contain 
somatostatin, 20% contain glucagon , and 35% con-
tain insulin. Islets were incubated with the labeled 
amino acids 3H-tryptophan and 35S-cystine, and islet 
proteins were separated with column chromatogra-
phy (P-10) and polyacrylamide gel electrophoresis 
(pH 9.5). Clea r peaks of radioactivity were found in 
fractions containing the largest quantity of somato-
statin immunoreactivity. 47 Synthetic cyclic soma-
tostatin migrated into the same fractions . Thus there 
is now good evidence that somatostatin is synthesized 
in situ in islet tissue and there is a lso preliminary 
evidence that there is a larger precursor form of 
somatostatin (prosomatostatin ). Precursor forms 
have been described for a number of other peptides 
including insulin and glucagon. 
There is currently great interest in defining the 
characteristics of the secretory control of somatosta-
tin as this should help solve some of the puzzles about 
its physiological role. Data is fragmentary , but stud-
ies by G. Patton and co-workers48 and E. Samo ls 
and co-workers49·50 in the isolated perfused canine 
and rat pancreas now show that somatostatin secre-
tion can be stimulated by glucagon and arginine. 
The present interpretation is th at glucagon probably 
has a direct influence upon the D cell, and that the 
arginine effect may be indirect, acting via local secre-
tion of glucagon by the A cell. 
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Somatostatin ' s contribution to the pathophy-
siology of diabetes has yet to be elucidated, but some 
provocative information is available. Following the 
induction of diabetes in rats with the B-cell toxin , 
streptozotocin, a significant increase of islet soma-
tostatin content was found using radioimmunoassay 
techniques. 51 This author has observed (unpublished 
data, 1976) that increased somatostatin in extracts of 
whole rat pancreas has been found with streptozoto-
cin, as well as with a lloxan, a different B-cell toxin. 
With immunofluorescent techniques it has been pos-
sible to show both hypertrophy and hyperplasia of 
islet D cells not only in streptozotocin diabetic rats 
but also in tissue from two juvenile-type human dia-
betics.52 These findings may be a secondary phenome-
non related to the hypersecretion of glucagon, or 
perhaps the hyposecretion of insulin known to occur 
in diabetes, or to some other factor. The critical 
question is whether there is increased islet somatosta-
tin secretion leading to reduced insulin secretion . 
Also, even though diabetics secrete excessive 
amounts of glucagon which contribute to hypergly-
cemia, they might secrete even more glucagon were it 
not for D-cell secretion of somatostatin . Therefore, 
the D-cell hypertrophy could have either a beneficial 
or detrimental influence upon diabetes . 
An understanding of somatostatin's physiologic 
importance may help us make sense of what is occur-
ring in disease states. There is good reason to think 
that somatostatin's effects are exerted locally. It 
seems no accident that cells containing somatostatin 
are located in close proximity to cells capable of 
responding to somatostatin. Because of this proxim-
ity and because of somatostatin's instability in blood, 
it would seem inefficient for this peptide to be trans-
ported through the circulation to distant organs. Un-
fortunately, it has not yet been possible to measure 
physiological levels of somatostatin in plasma. Local 
secretory mechanisms are probably important in 
many organs, but islets are particularly intriguing. 
There is now good evidence that local secretion by 
autonomic nerve terminals of norepinephrine and 
acetylcholine can influence both glucagon and insulin 
secretion. 53 Some data suggest that local insulin secre-
tion suppresses glucagon release from A cells54 and 
there is now reason to suspect that glucagon may 
stimulate insulin release, 55 that somatostatin may in-
hibit the secretion of insulin and glucagon , and that 
glucagon may stimulate somatostatin secretion. The 
potential interactions which take place in islet inter-
stitial spaces may be extraordinarily complex and 
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difficult to clarify. Another possible way in which 
different islet cells could communicate is through gap 
junctions. Small molecules have been shown to move 
from the cytoplasm of one cell into the cytoplasm of 
another through these structures. Gap junctions have 
been described as otcurring between B cells, and also 
between A and B cells, 56 but thorough studies of 
possible D-cell gap junctions are not yet available. 
Suggestions have also been made that there may be 
important electrical interactions between islet cells. 
Even though one can make many speculations 
about the possible importance of somatostatin in is-
lets and the gastrointestinal tract, no definitive effects 
have been elucidated. There is, however, evidence 
that somatostatin exerts a physiological influence on 
the pituitary. Injections of somatostatin antiserum 
into rats led to increases in growth hormone and TSH 
secretion, presumably by neutralizing somatostatin in 
the hypothalamic-hypophyseal portal circulation. 57 •58 
The finding that somatostatin is distributed through-
out extrahypothalamic areas of the central nervous 
system raises important questions about somatosta-
tin's possible role as a neurotransmitter. There is also 
much curiosity about the evolution and embryology 
of somatostatin, particularly since its presence is 
found in such diverse areas as the central nervous 
system, pancreatic islets, and gut. It is worth noting 
that another peptide, substance P, has recently been 
found in various parts of the brain including the 
hypothalamus, and the gut.7 
It was predictable that a "somatostatinoma" 
would eventually be found, and 0. P. Ganda and 
associates59 indicate that it has been. A 46-year-old 
woman with an eight-year history of well-docu-
mented diabetes mellitus was found to have a pan-
creatic islet cell tumor during a cholecystectomy. 
Clinically there was no evidence of its being an in-
sulinoma, glucagonoma, or a tumor of either the 
Zollinger-Ellison or pancreati~ cholera (Verner-Mor-
rison) type. Ultrastructurally the majority of the cells 
appeared to be of the D-type. The somatostatin con-
tent of the tumor was remarkably high (301 ng/ mg of 
tissue), and the content of insulin, glucagon, gastrin, 
and vasoactive intestinal peptide was negligible. 
Pathologically the tumor was judged to be a low-
grade malignancy, and metastatic tissue was found in 
one of the 38 resected lymph nodes. Remarkably, 
following surgical removal of the entire tumor, glu-
cose values returned to normal and have remained so 
for 16 months (a recent fasting blood sugar was 73 
mg/ I OOml and two-hour postprandial was 70 
9 
mg/ IOOml ). We hypothesized that the patient was 
diabetic because of the continued secretion of large 
amounts of somatostatin by her tumor. As men-
tioned above, experimental infusions of somatostatin 
in normal subjects produce a fall of blood glucose; 
this drop, however, is only transitory, lasting for a 
few hours; with a longer infusion, hyperglycemia de-
velops. Studies of insulin, glucagon, and growth hor-
mone secretion in response to an arginine infusion 
were done prior to surgery and the response of each 
hormone appeared to be diminished, as one might 
expect with chronic somatostatin exposure. Unfortu-
nately, it was not possible to repeat the study follow-
ing surgery . When a patient is found to have an 
apparently non-functioning pancreatic tumor of the 
islet cell type, especially if diabetes is also present, the 
possibility of a somatostatinoma shot.lid be consid-
ered. 
Somatostatin has proved to be infinitely more 
interesting than anyone might have imagined at the 
time of its discovery in 1973. Current interest in this 
unique peptide is focused upon its potential role in 
the pathophysiology and therapy of diabetes mellitus. 
It is probable that somatostatin also will come to 
occupy an increasingly prominent place in such di-
verse disciplines as cell biology, the neurosciences, 
endocrinology, and gastroenterology. 
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